Composition and uses thereof
US-2016144011-A1 · May 26, 2016 · US
Vaccine for falciparum malaria
US10213502B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10213502-B2 |
| Application number | US-201715607203-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 26, 2017 |
| Priority date | Dec 2, 2011 |
| Publication date | Feb 26, 2019 |
| Grant date | Feb 26, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides compositions and methods for preventing or reducing the severity of malaria.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating P. falciparum malaria in a subject or vaccinating against malaria comprising administering to the subject a composition comprising a purified PfGARP polypeptide antigen comprising the amino acid sequence of SEQ ID NO: 27 or a purified antigenic fragment thereof comprising the amino acid sequence of SEQ ID NO: 26. 2. The method of claim 1 , wherein said purified antigen or antigenic fragment thereof comprising the amino acid sequence of SEQ ID NO: 26 elicits an antibody immune response against PfGARP. 3. The method of claim 1 , wherein said subject is at least about 6-8 weeks of age. 4. The method of claim 1 , wherein said subject is an adolescent female or a female of childbearing age. 5. The method of claim 1 , wherein said composition is administered intramuscularly. 6. The method of claim 1 , further comprising administering a second vaccine. 7. The method of claim 6 , said second vaccine comprises RTS,S (Mosquirix) or MSP-1.
Assignees
Inventors
Classifications
characterised by the host/recipient, e.g. newborn with maternal antibodies · CPC title
against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids} · CPC title
Plasmodium · CPC title
- A61K39/015Primary
Hemosporidia antigens, e.g. Plasmodium antigens · CPC title
Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10213502B2 cover?
- The invention provides compositions and methods for preventing or reducing the severity of malaria.
- Who is the assignee on this patent?
- Rhode Island Hospital, Seattle Biomedical Res Institute
- What technology area does this patent fall under?
- Primary CPC classification A61K39/015. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Feb 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).